BioSpace News Archive

Verastem, Inc. announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 p.m.

Kymera Therapeutics Inc. announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases.

The Prescription Drug User Fee Act (PDUFA) date for [fam-] trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast cancer is set for the second quarter of 2020.

Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces that formal arbitration proceedings have been commenced by Elmar R. Burchardt

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), today announced the publication of an article describing the manufacturing process optimization of ADMA’s Intravenous Immunoglobulin (“IVIG”) products, BIVIGAM® and ASCENIV

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it will release financial results for the third quarter 2019 after the market closes on Thursday, October 31st, 2019.

Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its third quarter 2019 results on Monday, October 28, and host a conference call the same morning at 9:00 am EDT.

Medifast, Inc. (NYSE: MED), a leading manufacturer and distributor of clinically proven programs and healthy living products, will announce financial results for the third quarter ended September 30, 2019 on Thursday, November 7, 2019, after market close.

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its third quarter 2019 financial results before markets open on Thursday, October 31, 2019.

Emergency medical professionals can securely message and view patient medication histories at the scene to improve care continuity, quality, and safety